Research programme: anti-inflammatories - Avicenna
Alternative Names: DAV0601Latest Information Update: 16 Jul 2016
At a glance
- Originator Avicenna Pharma Development
- Class
- Mechanism of Action Sphingomyelin phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases; Ulcerative colitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in United Arab Emirates (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ulcerative-colitis in United Arab Emirates (PO, Tablet)
- 31 Mar 2009 Preclinical trials in Inflammatory bowel disease in United Arab Emirates (PO)